Recent advances in DNA sequencing technologies have allowed unprecedented insights into the genomic landscape of human tumours ([@bib32]). A unifying theme is emerging: cancers display extensive inter- and intra-tumoral genetic heterogeneity, with very few neoplasms resulting from a single recurrent genomic aberration ([@bib21]; [@bib44]). In parallel with those observations, many lines of evidence suggest that cancers may be driven by alterations that are epigenetic in nature, that is, they do not alter the primary DNA sequence ([@bib31]; [@bib48]). As epigenetic modifications are reversible and can be pharmacologically targeted ([@bib13]; [@bib27]), identifying the epigenetic drivers of cancer progression is thus a matter of utmost importance.

In the past decade, a number of chromatin regulators known to have key molecular functions in embryonic development have been identified as novel cancer-promoting genes ([@bib53]; [@bib58]). These epigenetic factors are thought to retain cancer cells in an undifferentiated state, thus enhancing their metastatic potential and resistance to treatment ([@bib5]; [@bib37]). The Polycomb group (PcG) family represents the typical example of such genes, as they can silence lineage-specific genes both in embryonic stem cells and multiple cancer types ([@bib9]). Polycomb group genes encode transcriptional repressors that assemble in a complex combinatorial manner to form two main Polycomb repressive complexes (PRC1 and PRC2) ([@bib41]; [@bib29]). In the classical model of PcG-mediated silencing, PRC2 trimethylates histone H3 at lysine 27 (H3K27me3) through the action of its catalytically active subunit EZH2 ([@bib11]). H3K27me3 can be directly recognised by one of five chromodomain-containing proteins (CBX2, 4, 6, 7 and 8), which subsequently recruit PRC1 to chromatin by simultaneously interacting with the E3 ubiquitin ligase Ring1B through a C-terminal domain ([@bib26]). This interaction brings Ring1B to H3K27me3 sites, where Ring1B ubiquitylates lysine 119 on histone H2A (H2AK119ub), further repressing transcription at target loci ([@bib50]). Interestingly, PRCs can also act independently of each other as recent studies have shown that PRC1 can silence genomic regions that are not marked by H3K27me3 ([@bib47]). Moreover, some CBX-containing PRC1 complexes are devoid of ubiquitin ligase activity despite retaining gene-silencing properties ([@bib19]). Although PcG proteins may act through different pathways in different cancer types, PcG gain of function generally associates with an undifferentiated cellular state and aggressive clinical behaviour ([@bib8]).

Whereas EZH2 and BMI-1 have been the two most heavily investigated PcG genes in the context of human neoplasms ([@bib4]; [@bib10]), emerging evidence supports a critical role for the CBX proteins in cancer initiation and progression. All CBX family members share a conserved N-terminal chromodomain but display non-homologous sequences in their C-terminus, accounting for their non-redundant functions ([@bib54]). Distinct CBX proteins interact with a wide range of macromolecules including DNA, non-coding RNAs, and numerous other proteins ([@bib7]; [@bib52]). Furthermore, individual CBX family members can be differentially expressed, undergo alternative splicing, harbour distinct post-translational modifications, and lie under the control of different microRNAs ([@bib36]). All of these regulatory steps affect the function of individual CBX protein and allow for tremendous complexity in PRC1 activity and sequence specificity.

Individual CBX proteins are defined by distinct C-terminal sequences that underlie their specific properties. The structural differences between the CBX family members are also reflected in the diversity of molecular functions they can accomplish in the context of cancer cells. For example, CBX4 possesses SUMO activity and is thought to have important roles in cellular proliferation and DNA damage repair in some human tumours ([@bib57]; [@bib55]). Conversely, SNPs in CBX6 have been reported in genome-wide association studies (GWASs) of bladder cancer although their functional implications have not been fully elucidated ([@bib40]). CBX7 has been the most extensively investigated CBX family member and exhibits cancer type-specific activity in human tumours. Most studies report a widespread oncosuppressive function ([@bib17]), notably in brain ([@bib20]), colon ([@bib38]), and lung cancers ([@bib18]). However, other investigations have revealed an oncogenic role for CBX7 ([@bib34]; [@bib61]) occurring mainly through silencing of CDKN2A and CDKN2B loci, which encode the cyclin-dependent kinase inhibitors p14^ARF^, p15^INK4B^, and p16^INK4A^ ([@bib6]). Finally, CBX8 was found to be essential for MLL/AF9 leukemogenesis ([@bib46]) in addition to its ability to silence the CDKN2A locus ([@bib15]). Despite solid evidence implicating these four CBX family members in neoplastic transformation, no study has directly addressed the role of CBX2 in human cancers.

Emerging evidence supports a role for CBX2 in cellular proliferation. Loss of M33, the murine CBX2 ortholog, impairs progression through the S phase of cell cycle in an E2F-dependent mechanism, which is consistent with the decreased cellularity of hematopoietic organs in M33-KO mice ([@bib12]). In addition, CBX2 directly binds the tumour-suppressive CDKN2A and CDKN2B loci in young and proliferative fibroblasts but progressively becomes absent from this chromosomal region as the cells undergo senescence and cell cycle arrest ([@bib1]). Furthermore, experiments conducted in mice have demonstrated that unphosphorylated M33 is present in the cytoplasm of mature hepatocytes, but becomes phosphorylated and translocates to the nucleus in proliferative hepatocytes during the liver regeneration ([@bib35]). Interestingly, studies have shown that CBX2 phosphorylation also increases its affinity to H3K27me3 in addition to inducing its nuclear translocation, which is consistent with cell cycle-dependent regulation of CBX2 activity ([@bib25]). Finally, Grau *et al* have demonstrated that CBX2 is the only human CBX family member able to induce chromatin compaction ([@bib23]). Elegant studies based on electron microscopy have revealed that this feature of CBX2 has mediated a highly positively charged region located in its C-terminus not found in any other PcG member, thus suggesting a unique and crucial function for CBX2 in PcG-mediated repression.

On the basis of the critical role played by CBX2 in cellular proliferation and the emerging evidence implicating Polycomb-mediated silencing in tumour biology, we postulated that CBX2 may represent an important component in cancer initiation and progression. Given the lack of literature addressing the implications of CBX2 in a neoplastic context, we conducted a meta-analysis of CBX2 in human cancers at the genomic and transcriptomic level using publicly available databases. We report that CBX2 downregulation and inactivating genetic mutations represent extremely rare events in human tumours. Furthermore, we also provide the first evidence that CBX2 genomic amplification and mRNA upregulation predict metastatic progression and poor overall survival (OS) in multiple cancer types, notably those arising from the breast.

Materials and methods
=====================

COSMIC database analysis
------------------------

The COSMIC database (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>) ([@bib16]) was used to extract all data relevant to our analysis of genetic alterations at the CBX2 locus. All data were collected after 20 October 2013, and a final revision of all acquired data was performed between 1 July and 21 July 2013. All data originating from the COSMIC database are specifically mentioned either in the main text, the figure legend, or both. All the raw data extracted from the COSMIC database can be found in [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Oncomine database analysis
--------------------------

All transcriptomic data used in this manuscript were extracted from the Oncomine platform ([www.oncomine.com](http://www.oncomine.com)) ([@bib39]) after 20 October 2013, and a final revision of all acquired data was performed between 1 July and 21 July 2013. Data were acquired in an unbiased manner by compiling all the Oncomine studies that showed significantly altered CBX2 expression at the threshold set for each individual analysis. Significant studies in which at least one analysed group was comprised of three patients or less were excluded. All data originating from the Oncomine database are specifically mentioned either in the main text, the figure legend, or both. All the raw data extracted from the Oncomine database can be found in [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Human Protein Atlas database analysis
-------------------------------------

The image of CBX2 protein sequence and domains used in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} was obtained from the Protein Atlas database (<http://www.proteinatlas.org/>) ([@bib49]).

### Assessment of clinical correlations for genes within the minimal common region (MCR) of CBX2 amplification

TCGA breast cancer copy number data were downloaded from Cancer Genomics Browser (<https://genome-cancer.ucsc.edu/>) and all tumours containing CBX2 gains were determined. We filtered the segments with gain (logR\>0.3) and at least 100 kb in size and mapped the MCR, defined by the sample with the smallest region containing CBX2. We then determined the Spearman copy number--expression correlation for genes mapping to the region assessed. Those with significant correlation (*P*\<0.05 Spearman) were further analysed for survival associations using the Curtis Breast data set on Oncomine and all breast cancer samples from the KMplotter resource (<http://kmplot.com/analysis/>) ([@bib33]).

Statistical analysis
--------------------

Unless otherwise mentioned, all analyses were done using *P*⩽0.05 as the significance threshold. GraphPad Prism software (version 6, GraphPad Software Inc., La Jolla, CA, USA) was used for all statistical analyses except for the multivariate analysis of variance (MANOVA) and the Cox proportional hazards (COXPH) regression, which were done using R statistical software (GNU, freely available at <http://www.r-project.org/>).

Results
=======

Genomic analysis of the CBX2 locus
----------------------------------

As the first step of our systematic meta-analysis to study CBX2 expression in human cancers, we analysed genomic alterations at the CBX2 locus using the COSMIC database, a resource designed to store and display somatic mutation information and related details ([@bib16]). Strikingly, there was an extremely low frequency of alterations disrupting CBX2 function. In 8013 tumour samples spanning 29 tissue types, we did not find a single translocation, homozygous loss, insertion/deletion, or any other inactivating large-scale chromosomal abnormalities ([Figure 1A](#fig1){ref-type="fig"}). In total, only 40 point mutations were recorded at the *CBX2* gene in these tumours (overall frequency=0.5%). The CBX2 mutation frequency is thus considered very low, as high-frequency mutations are typically described as being over 20% and intermediate frequency as being between 2 and 20% ([@bib30]). Further analysis revealed that of those 40 mutations, 2 were nonsense and 22 were missense, whereas 17 were silent mutations, which did not have any effect on CBX2 protein sequence ([Figure 1B](#fig1){ref-type="fig"}). These point mutations were distributed evenly across all tissues, with no tumour type having a marked increase in CBX2 mutation frequency ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). The mutations were concentrated in regions where CBX2 is predicted to be highly disordered and hydrophilic, and within these regions their distribution was relatively homogenous ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In addition, no single residue within the CBX2 protein was mutated more than twice. Interestingly, there was a complete absence of point mutations in the CBX2 chromodomain, the region responsible for H3K27me3 binding ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Overall, the lack of large-scale genomic aberration and the non-synonymous mutation frequency of 0.3% make it unlikely that alterations at the CBX2 locus impact cancer cell phenotype.

The low frequency of genomic CBX2 disruption led us to investigate whether CBX2 copy number increases are favoured during oncogenesis. To address this question, we first analysed the amplification profile of the CBX2 locus in human neoplasms using the COSMIC database. In contrast with the rare nature of CBX2-inactivating mutations, we uncovered that *CBX2* gene amplifications occur frequently in a number of tumour types. Overall, 714 out of 8013 samples from the COSMIC database had undergone copy number gain (CNG) at the CBX2 locus (overall frequency: 8.9% see [Figure 2](#fig2){ref-type="fig"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Interestingly, the distribution of these amplifications was not homogenous across all tumour types. We observed five neoplasms in which the CBX2 CNG frequency ranged between 3 and 15%: those originating from the central nervous system, colon, endometrium, pancreas, and kidneys ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Furthermore, three cancer types harboured a frequency of CBX2 amplification \>30%: tumours of the ovaries (34.0%), breast (34.5%), and lungs (35.5%), suggesting that CBX2 copy number increases may provide a selective advantage to cancer cells.

Transcriptomic analysis of CBX2 expression in human cancers
-----------------------------------------------------------

As our genomic analysis revealed recurrent CNGs and very rare inactivating mutations at the CBX2 locus, we next investigated whether this trend would also be reflected at the mRNA level. Using the Oncomine database ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}) ([@bib39]), we identified a total of 25 studies that showed significant upregulation (FC\>2, *P* value \<0.001, top 10% over/underexpressed) in cancer compared with normal tissue ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Strikingly, not a single study reported downregulation of CBX2 using the same inclusion criteria ([Figure 3](#fig3){ref-type="fig"}), once again implying an important functional role in cancer cells. The total number of patients in the 25 studies showing CBX2 upregulation in cancer tissues is 3848 compared with 0 for CBX2 downregulation ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). In the studies harbouring CBX2 overexpression, fold changes varied between 2.1 and 15, and the *P* values between 4.0E-3 and 3.6E-73 ([Figure 3](#fig3){ref-type="fig"}). The most represented cancer types in the CBX2-overexpressed studies were those originating from the colon (29.6%), breast (18.5%), stomach (14.8%), and lungs (11.1%). These results demonstrate a clear bias towards CBX2 upregulation and complement the genomic analysis that hinted towards a selective pressure to maintain CBX2 function.

Polycomb group complexes are known to repress the tumour-suppressive loci CDKN2A (encoding p14^ARF^ and p16^INK4A^) and CDKN2B (encoding p15^INK4B^) in many human cancers ([@bib2]). We thus sought to determine whether CBX2 overexpression correlated with silencing of the *CDKN2A/B* genes. Interestingly, we found that neither p14^ARF^ nor p16^INK4A^ were downregulated in any of the 25 studies with CBX2 overexpression ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). However, p15^INK4B^ was found to be downregulated in 10 of those 25 studies (40%) using the same cut-off as for CBX2 (FC\>2, *P* value \<0.01, top 10% underexpressed). Further analysis revealed that 8 of the 10 studies with concomitant CBX2 upregulation and p15^INK4B^ downregulation occurred specifically in the colorectal cancer ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). However, when using Spearman correlations to investigate the direct relationship between CBX2 and CDKN2A/B, not a single study showed a statistically significant correlation ([Table 1](#tbl1){ref-type="table"}, Spearman correlation of *R*^2^\>0.1, even in colorectal cancer). Taken together, analysis of CBX2 mRNA levels revealed lack of CBX2 downregulation contrasted by frequent CBX2 overexpression, an event that occurred independently of CDKN2A/B silencing.

Clinical correlations of differential CBX2 expression
-----------------------------------------------------

Given the widespread CBX2 upregulation in cancerous compared with normal tissues, we investigated whether CBX2 expression was also correlated with clinical indicators of tumour progression. Metastasis was the first parameter we assessed. Using the Oncomine database ([@bib39]), we found nine studies exhibiting significantly (FC⩾1.5, *P*⩽0.05) increased CBX2 mRNA levels in metastatic compared with primary tumours ([Table 2](#tbl2){ref-type="table"}). Prostate cancer (PCa) was the most represented tumour type, accounting for three of the five most significant studies. Sarcoma and breast cancer followed with two studies each displaying CBX2 upregulation in metastatic disease. In contrast with the strong CBX2 upregulation observed in disseminated tumours, not a single study with CBX2 underexpression could be detected using the same parameters ([Table 2](#tbl2){ref-type="table"}), consistent with a selection against CBX2 loss of function in metastatic cells.

Next, we investigated whether differential CBX2 expression and genomic copy number were associated with poor clinical outcome in human malignancies. We queried the Oncomine database for studies in which CBX2 mRNA levels were significantly altered between alive and deceased patients at 1, 3, and 5 years after diagnosis using an FC\>1.2 and *P*\<0.05 as inclusion criteria ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). After 1 year, the number of studies with CBX2 overexpression (eight) was almost two-fold higher than those with CBX2 underexpression (five) ([Figure 4A](#fig4){ref-type="fig"} and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). Furthermore, there was a striking difference between the number of studies in which CBX2 mRNA was upregulated compared with those which displayed CBX2 downregulation in patients who were deceased compared with those who were alive at 3 and 5 years post diagnosis (17/1 and 16/2, respectively, see [Figure 4A](#fig4){ref-type="fig"} and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). To ensure that the number of studies showing CBX2 upregulation was higher than those with CBX2 downregulation across all three time points, we performed a chi-square test and found a statistically significant difference between the studies with high and low CBX2 (*P*\<0.00001, chi-square). Interestingly, some cancer types in particular showed a recurrent inverse correlation between high CBX2 mRNA levels and lower OS. Notably, tumours of the breast (five and five), central nervous system (two and two), and lungs (one and three) were among the most represented cancer types for this analysis at 3 and 5 years, respectively ([Figure 4A](#fig4){ref-type="fig"}). We also found three studies of head and neck tumours in which significantly decreased, not increased, levels of CBX2 led to lower OS. In addition, CBX2 CNG could also be associated with clinical outcome. Analysis of the Oncomine database revealed an increase in CBX2 copy number in metastatic compared with primary pancreatic cancer ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}, *P*\<0.001). Moreover, CBX2 CNG was also inversely correlated with OS in oligoastrocytoma and ovarian cancer at 3 years ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}, *P*=0.02 for both), and in oligoastrocytoma at 5 years ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}, *P*=0.02). Thus, our results demonstrate that both *CBX2* gene amplification and mRNA upregulation may harbour prognostic significance.

To further assess the relationship between CBX2 and individual clinical variables, we conducted a MANOVA in one cohort for each of the breast, lung, and colorectal cancers from the Oncomine platform. All significant covariates (*P*\<0.05) in the MANOVA were further assessed using univariate analyses. We found that CBX2 was significantly associated with sex in the colon cancer, with higher expression observed in females ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}, TCGA colorectal, *P*\<0.01, Mann--Whitney *U-*test). In the analysed lung cancer data set, subtype was the only clinical covariate associating with CBX2, with higher CBX2 expression in squamous cell carcinoma compared with lung adenocarcinoma ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}, Bild Lung, *P*\<0.05, Mann--Whitney *U-*test). Finally, MANOVA conducted on the Curtis Breast data set revealed a highly significant association between CBX2 and age, subtype, and grade that was confirmed via Kruskal--Wallis test ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}, all *P*s\<10^−15^, Kruskal--Wallis test). More specifically, higher CBX2 expression correlated with younger age, basal-like subtype, and higher grade, all of which are linked to poor patient prognosis. We therefore conducted a COXPH regression on the Curtis Breast data set to further explore the relationship between CBX2 and clinical outcome. Interestingly, we found that behind age, CBX2 was the second covariate most significantly associated with patient survival ([Table 3](#tbl3){ref-type="table"}, COXPH, *P*\<0.001), suggesting a role for CBX2 in promoting aggressive disease progression.

Finally, we investigated whether CBX2 is a potential driver of the recurrent 17q25.3 copy gains we observed. We used multiple criteria to investigate genes mapping to the MCR of amplification containing CBX2, including copy number expression association, expression in tumours compared with normals, and survival association, as these features could highlight the gene that is most likely to be driving the 17q25.3 amplicon. As CBX2 was recurrently amplified and differentially expressed in breast cancer, we investigate the clinical implications of the CBX2 amplicon in breast cancer. We first used breast cancer TCGA copy number data from the Cancer Genomics Browser ([@bib60]; <https://genome-cancer.ucsc.edu/>) to identify all gained genomic segments containing CBX2. We then filtered the segments with gain (defined by having a log ratio \>0.3) and at least 100 kb in size and mapped the MCR, which is defined by the sample with the smallest region containing CBX2. We found that the MCR contained three genes: ENPP7, CBX2, and CBX8, present at 17q25.3 ([Figure 5A and B](#fig5){ref-type="fig"}). We next assessed the correlation between copy number and the expression of genes mapping to the region using Spearman correlation. ENPP7 had a negative correlation, indicating that its amplification did not result in increased expression. In contrast, a weak but significant positive correlation was observed for both CBX2 and CBX8 ([Supplementary Table S9](#sup1){ref-type="supplementary-material"}, *P*\<0.0001, Spearman). To determine whether either of the two genes was associated with patient survival, we performed a Mantel--Cox log-rank test for both CBX2 and CBX8, comparing survival of patients with expression ranking in the top and bottom quartiles of expression. We report that elevated CBX2 levels, but not CBX8, significantly predicts lower OS in breast cancer ([Figure 5C and D](#fig5){ref-type="fig"}, CBX2 *P*\<0.0001; CBX8 *P*=0.49, Mantel--Cox log-rank test). were reproducible, we also performed log-rank test on CBX2 and CBX8 using the KMplotter (<http://kmplot.com/analysis/>) ([@bib33]). Once again, we found that *CBX2* was the only gene within the MCR that was able to significantly predict lower OS ([Figure 5E and F](#fig5){ref-type="fig"}, *P*\<0.05, log-rank test). Overall, we demonstrate that CBX2 is frequently gained in breast cancer, which leads to its increased expression and associates with poor patient prognosis, suggesting that it is a candidate driver of the 17q25.3 amplicon.

In summary, genomic analysis has revealed that genetic alterations resulting in loss of function represent extremely infrequent events at the CBX2 locus. In contrast, recurrent amplifications were observed in multiple cancer types. In addition, transcriptomic analysis revealed a propensity for CBX2 upregulation in the following four independent scenarios: (1) cancer *vs* normal tissues; (2) metastatic *vs* primary tumours; (3) dead *vs* alive at 3 years; and (4) dead *vs* alive at 5 years ([Supplementary Table S10](#sup1){ref-type="supplementary-material"}). Surprisingly, with the exception of CDKN2B in the colorectal cancer, CBX2 overexpression was not correlated with silencing of the tumour-suppressive CDKN2A or CDKN2B loci.

Discussion
==========

Our results demonstrate a clinically relevant increase in CBX2 copy number and expression in human cancer. Given the very low frequency of CBX homozygous loss, point mutation, and underexpression, we believe CBX2 is likely to have an important functional role in tumour cells. In parallel, transcriptomic analysis of CBX2 expression revealed a strong bias towards CBX2 upregulation, although this alteration was observed at different stages among the various tumour types, indicating some context specificity in CBX2 activity and binding partners. Overall, breast cancer displayed the most significant associations with CBX2 alterations, exhibiting an overall frequency of CBX2 amplification exceeding 30%. We demonstrated that CBX2 copy number increases correlated with increased CBX2 expression, which is significantly associated with lower OS. Of all the genes present in the MCR containing CBX2, only CBX2 has prognostic relevance, suggesting that CBX2 displays a driving role in the progression of breast cancer. As CBX2 and CBX8 share a conserved chromodomain but largely differ in their C-terminus ([@bib54]), we believe further investigation is required to elucidate the structural differences that may underlie the potential cancer-promoting role of CBX2.

Given that many breast cancers also harbour EZH2 gain of function ([@bib22]; [@bib28]), an interesting possibility is that CBX2 upregulation represents a key adaptation necessary to perpetuate EZH2\'s oncogenic activity. This therefore implies an important role for the ability of CBX2 to interact with H3K27me3 and is consistent with our observation that missense mutations are excluded from the chromodomain of CBX2. Given that chromodomains act as protein--RNA binding modules ([@bib3]), we also suspect that CBX2 may be interacting with specific long non-coding RNAs (lncRNAs), which could fine tune its target specificity in a context-dependent manner. Interestingly, EZH2 and H3K27me3 also regulate the expression of several tissue-specific lncRNAs ([@bib56]; [@bib24]). As many loci encoding lncRNA are rich in AT repeats and CBX2 contains an AT hook domain that can interact with those regions ([@bib42]), it is conceivable that EZH2 and CBX2 directly regulate the lncRNAs that themselves determine PcG target specificity.

Prostate cancer is another neoplasm in which EZH2 overexpression represents a key hallmark ([@bib53]; [@bib51]), and interestingly it was the cancer type in which CBX2 upregulation most significantly correlated with metastatic progression. The frequent upregulation of many PcG family members ([@bib51]), coupled with the prognostic significance of a Polycomb repressive signature in PCa ([@bib59]), support the idea that PcG complexes undergo gain of function in metastatic disease. As opposed to breast cancer, we could not find any significant differential CBX2 expression in neoplastic tissues compared with normal ones, indicating that CBX2 upregulation likely represents a late event in PCa progression. Whereas the presence of metastases represents the most valuable indicator of PCa prognosis, we did not find any correlations between CBX2 expression and OS. We attribute this result to a technical limitation of the Oncomine database, which can only calculate survival at 1, 3, and 5 years. As PCa is generally a slow-growing disease and metastases can appear years after initial diagnosis ([@bib43]), it is likely that analysing differences in OS strictly below 5 years post diagnosis may be too early to achieve statistical significance.

Our results conclusively demonstrate a recurrent CBX2 upregulation frequently correlating with metastasis and lower OS in numerous cancer types. This analysis paves the way for functional studies aimed at identifying the molecular mechanisms through which CBX2 may promote tumour initiation and progression. However, one limitation of our meta-analysis is that it does not allow for an in-depth characterisation of subtype-specific CBX2 expression. For example, it is thus possible that CBX2 expression is markedly high in one molecularly or histologically characterised subtype while being low in another from a given neoplasm, something that could not be determined from our analysis. Nonetheless, by using the COSMIC and Oncomine databases we were able to analyse over 40 000 patient samples in a fully unbiased manner, which allowed us to observe a genotranscriptomic profile for CBX2 that was consistent with that of an oncogene.

Finally, the very low frequency of CBX2 mutation and underexpression suggest that the therapeutic inhibition of CBX2 might represent a valuable clinical strategy for the treatment of many human cancers. We report aberrant regulation of CBX2 in the breast, lung, colorectal, prostate, brain, and haematopoietic tumours, all of which rank among the 10 deadliest neoplastic diseases worldwide and are in dire need of novel therapeutics. Furthermore, epigenetic alterations are reversible and recent studies have highlighted the possibility of targeting histone readers with small-molecule inhibitors ([@bib14]; [@bib45]). Taken together, our work has identified a putative oncogenic role for CBX2 in numerous tumour types and has provided the rationale for the design of novel CBX2-targeting therapies.
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![**Extremely rare occurrence of genetic mutations disrupting CBX2 function in human cancers (COSMIC database)** (**A**) Percentage of specific inactivating genetic alterations at the CBX2 locus. (**B**) Distribution and frequency of CBX2 point mutations.](bjc2014474f1){#fig1}

![**High frequency of CBX2 amplification across different tumour types (COSMIC database).**](bjc2014474f2){#fig2}

![**Marked upregulation of CBX2 in cancerous compared with normal tissues (Oncomine database).** (**A**) Number of studies displaying significant CBX2 upregulation or downregulation in cancer *vs* normal tissues at different *P* values. The total number of patients in the significant studies is shown in brackets. (Inclusion criteria: FC⩾2, top 10% under/overexpressed, Student\'s *t*-test.) (**B**) Tissue distribution of the 25 studies harbouring significant CBX2 upregulation at *P*⩽0.001 (Student\'s *t*-test).](bjc2014474f3){#fig3}

![**Differential CBX2 expression predicts OS.** (**A**) Number of oncomine studies with either significant CBX2 up- or downregulation (FC⩾1.2, *P*⩽0.05, Student\'s *t*-test) in patients who are dead compared with alive at 1, 3, and 5 years post diagnosis (CBX2 high *vs* CBX2 low; *P*\<0.00001, chi-square test). (**B**) Sex-specific CBX2 expression in TCGA colon (*P*=0.0015, Mann--Whitney *U*-test). (**C**) Subtype-specific CBX2 expression in Bild Lung (*P*=0.03, Mann--Whitney *U*-test). (**D**) Subtype-specific CBX2 expression in Curtis Breast (*P*\<0.0001, Kruskal--Wallis test). (**E**) Grade-specific CBX2 expression in Curtis Breast (*P*\<0.0001, Kruskal--Wallis test).](bjc2014474f4){#fig4}

![**CBX2 as the driver within the MCR of its amplicon.** (**A**) Identification of the CBX2 MCR on 17q25.3. (**B**) Genes present within the CBX2 MCR. Log-rank test assessing link with OS for (**C**, **E**) CBX2 (*P*\<0.05) and (**D**, **F**) CBX8 (*P*\>0.05).](bjc2014474f5){#fig5}

###### Spearman correlation between CBX2 and CDKN2A/B in the dat sets displaying CBX2 upregulation in malignant compared with normal tissues

  **Data set**              **Patients,** ***n***   ***R***^**2**^ **CDKN2A**   ***R***^**2**^ **CDKN2B**
  ------------------------- ----------------------- --------------------------- ---------------------------
  Brune lymphoma            42                      0.00                        0.05
  Cho gastric               71                      0.02                        0.07
  Crabtree uterus           50                      0.05                        0.01
  Curtis breast             1992                    0.01                        0.00
  Derrico gastric           38                      0.02                        0.00
  Hong colorectal           70                      0.04                        0.00
  Hou lung                  91                      0.00                        0.01
  Korkola seminoma          101                     0.02                        0.01
  Lee bladder               188                     0.01                        0.04
  Richardson breast 2       40                      0.12                        0.02
  Skrzypczak colorectal     81                      0.01                        0.03
  Skrzypczak colorectal 2   20                      0.03                        0.01
  Sun brain                 157                     0.01                        0.00
  TCGA breast               532                     0.11                        0.05
  TCGA colorectal           215                     0.00                        0.00

Abbreviation: CDKN=cyclin-dependent kinase inhibitor.

###### List of studies with differential CBX2 expression between metastatic and primary tumours

  **Alteration**   **Rank**   **Study name**        **Cancer type**   **Primary,** ***n***   **Metastatic,** ***n***   **Total,** ***n***   **Fold change**    ***P***-**value**
  ---------------- ---------- --------------------- ----------------- ---------------------- ------------------------- -------------------- ----------------- -------------------
  Upregulation     1          Chandran prostate     Prostate cancer   10                     21                        31                   7.8                     1.7E-12
                   2          Bittner breast        Breast cancer     327                    9                         336                  1.9                    3.2E--05
                   3          Varambally prostate   Prostate cancer   7                      6                         13                   9.2                    1.3E--04
                   4          Segal sarcoma 2       Sarcoma           46                     4                         50                   13                     4.4E--04
                   5          Grasso prostate       Prostate cancer   13                     17                        30                   1.9                    4.0E--03
                   6          Riker melanoma        Melanoma          16                     40                        56                   1.6                    6.0E--03
                   7          Radvanyi breast       Breast cancer     41                     4                         45                   3.1                    9.0E--03
                   8          Bittner sarcoma       Sarcoma           42                     10                        52                   1.7                    1.1E--02
                   9          Liao liver            Liver cancer      4                      6                         10                   4.9                    2.3E--02
  Downregulation   **---**    None found            **---**           **---**                **---**                                        **---**                 **---**

Oncomine database; inclusion criteria: FC⩾1.5, *P*⩽0.05, top 10% under/overexpressed, Student\'s *t*-test.

###### Cox proportional hazards regression for CBX2 in Curtis Breast data set

  **Curtis breast**   **Coef**   **exp(coef)**   **s.e. (coef)**   ***z***   ***P***-**value**
  ------------------- ---------- --------------- ----------------- --------- -------------------
  CBX2                0.108      1.11            0.03369           3.205     0.0013
  Age                 0.0316     1.03            0.00312           10.123    0
  Grade 2             0.1439     1.15            0.15029           0.957     0.34
  Grade 3             0.3413     1.41            0.15505           2.201     0.028
  Basal subtype       0.2722     1.31            0.12925           2.106     0.035
  Luminal B subtype   0.2495     1.28            0.09536           2.617     0.0089
  Her2 subtype        0.3634     1.44            0.12174           2.985     0.0028
  Normal subtype      0.2839     1.33            0.13662           2.078     0.038

Abbreviations: CBX2=chromobox protein 2; Coef=coefficient; exp=exponent.
